anti-NGF siRNA (Lipella)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Nameanti-NGF siRNA (Lipella)
Drug Alias Nameliposomal siRNA therapy (Lipella)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsUrinary Bladder, OveractiveCystitis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesLipella Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLipella Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsUrinary Bladder, OveractiveCystitis

Other Information

ATC CodeN/A
Related LinksN/A